Dabigatran Concept

subject area of

• 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Academic Article
• A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery  Academic Article
• A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN)  Academic Article
• A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system  Academic Article
• A logical approach to surgical thromboprophylaxis  Academic Article
• Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial  Academic Article
• Activated prothrombin complex concentrate for dabigatran-associated bleeding  Academic Article
• Acute management of bleeding in patients on novel oral anticoagulants  Academic Article
• Additional Events in the RE-LY Trial  Academic Article
• Adherence to anticoagulant treatment with dabigatran in a real‐world setting  Academic Article
• Advances in treatment and management  Academic Article
• Advantages and limitations of the new anticoagulants  Academic Article
• After PCI in AF, dual antithrombotic therapy with dabigatran reduced bleeding compared with triple therapy  Academic Article
• An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery  Academic Article
• Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial  Academic Article
• Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation  Academic Article
• Another Dimension of Safety in the Prescription of Anticoagulants for Nonvalvular Atrial Fibrillation  Academic Article
• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer  Academic Article
• Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer  Academic Article
• Antithrombotic Therapy for Atrial Fibrillation  Academic Article
• Approach to the new oral anticoagulants in family practice: part 1: comparing the options.  Academic Article
• Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.  Academic Article
• Assessing the impact of dabigatran and warfarin on health-related quality of life: Results from an RE-LY sub-study  Academic Article
• Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation  Academic Article
• Barriers and facilitators to optimal oral anticoagulant management: a scoping review  Academic Article
• Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time  Academic Article
• Beyond Unfractionated Heparin and Warfarin  Academic Article
• Bleeding Complications and Management on anticoagulant therapy  Academic Article
• Bleeding and antidotes in new oral anticoagulants  Academic Article
• Bleeding events with dabigatran or warfarin in patients with venous thromboembolism  Academic Article
• Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study  Academic Article
• Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience  Academic Article
• Bleeding with direct oral anticoagulants vs warfarin: clinical experience  Academic Article
• Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter  Academic Article
• Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)  Academic Article
• Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial  Academic Article
• Causes of Death and Influencing Factors in Patients With Atrial Fibrillation  Academic Article
• Changes in Renal Function in Patients With Atrial Fibrillation  Academic Article
• Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• Clinical implications of reversal agents for direct oral anticoagulants  Academic Article
• Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications  Academic Article
• Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure  Academic Article
• Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development  Academic Article
• Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study  Academic Article
• Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?  Academic Article
• Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)  Academic Article
• Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease  Academic Article
• Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial  Academic Article
• Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial  Academic Article
• Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations  Academic Article
• Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism  Academic Article
• Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation  Academic Article
• Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial  Academic Article
• Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)  Academic Article
• Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist  Academic Article
• Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation  Academic Article
• Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective  Academic Article
• D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy  Academic Article
• DOAC–associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature  Academic Article
• Dabigatran Etexilate  Academic Article
• Dabigatran Etexilate: Future Directions in Anticoagulant Treatment  Academic Article
• Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery  Academic Article
• Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment  Academic Article
• Dabigatran Reversal with Idarucizumab  Academic Article
• Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke  Academic Article
• Dabigatran Versus Warfarin  Academic Article
• Dabigatran Versus Warfarin in Patients With Atrial Fibrillation  Academic Article
• Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function  Academic Article
• Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation  Academic Article
• Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management  Academic Article
• Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?  Academic Article
• Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial  Academic Article
• Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial  Academic Article
• Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation  Academic Article
• Dabigatran etexilate and reduction in serum apolipoprotein B  Academic Article
• Dabigatran etexilate for prevention of venous thromboembolism  Academic Article
• Dabigatran following acute transient ischemic attack and minor stroke II (DATAS II)  Academic Article
• Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial  Academic Article
• Dabigatran in clinical practice: Contemporary overview of the evidence  Academic Article
• Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial  Academic Article
• Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve‐Induced Thrombin Generation  Academic Article
• Dabigatran monitoring made simple?  Academic Article
• Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature  Academic Article
• Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II  Academic Article
• Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.  Academic Article
• Dabigatran versus Warfarin for Venous Thromboembolism  Academic Article
• Dabigatran versus Warfarin in Patients with Atrial Fibrillation  Academic Article
• Dabigatran versus Warfarin in Patients with Mechanical Heart Valves  Academic Article
• Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism  Academic Article
• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada  Academic Article
• Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study  Academic Article
• Dabigatran-Induced Acute Hepatitis  Academic Article
• Dabigatran-related coagulopathy: when can we assume the effect has “worn off”?  Academic Article
• Dabigatran: ready for prime time?  Academic Article
• Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home  Academic Article
• Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran  Academic Article
• Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE)  Academic Article
• Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding  Academic Article
• Direct Oral Anticoagulants and Myocardial Infarction  Academic Article
• Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies  Academic Article
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials  Academic Article
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.  Academic Article
• Direct oral anticoagulants: evidence and unresolved issues  Academic Article
• Early Dabigatran Treatment After Transient Ischemic Attack and Minor Ischemic Stroke Does Not Result in Hemorrhagic Transformation  Academic Article
• Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure  Academic Article
• Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events  Academic Article
• Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi‐database cohort study with meta‐analysis  Academic Article
• Effects of dabigatran according to age in atrial fibrillation  Academic Article
• Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants  Academic Article
• Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation  Academic Article
• Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation  Academic Article
• Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS₂ Score  Academic Article
• Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -  Academic Article
• Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial  Academic Article
• Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis  Academic Article
• Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER^®, RE-COVER™ II, and RE-MEDY™  Academic Article
• Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation  Academic Article
• Enhanced TRAP-induced platelet aggregation with dabigatran — Clinical perspective  Academic Article
• Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty  Academic Article
• Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran  Academic Article
• Evolving use of new oral anticoagulants for treatment of venous thromboembolism  Academic Article
• Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism  Academic Article
• Factor Xa and thrombin as targets for new oral anticoagulants  Academic Article
• Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies  Academic Article
• Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding  Academic Article
• Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study  Academic Article
• Hemodialysis for the treatment of dabigatran‐associated bleeding: a case report and systematic review  Academic Article
• Home-monitoring of oral anticoagulation vs. dabigatran  Academic Article
• How I treat target-specific oral anticoagulant–associated bleeding  Academic Article
• How can we reverse bleeding in patients on direct oral anticoagulants?  Academic Article
• Idarucizumab  Academic Article
• Idarucizumab for Dabigatran Reversal  Academic Article
• Idarucizumab for Dabigatran Reversal — Full Cohort Analysis  Academic Article
• Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds  Academic Article
• Idarucizumab for dabigatran overdose  Academic Article
• In-vitro assessment of the effect of dabigatran on thrombosis of adult and neonatal plasma  Academic Article
• Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation  Academic Article
• Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation  Academic Article
• Intensity and Quality of Warfarin Anticoagulation in Chinese Patients  Academic Article
• Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation  Academic Article
• International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants  Academic Article
• Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran  Academic Article
• Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials  Academic Article
• Is there really misuse and abuse of dabigatran?  Academic Article
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Academic Article
• Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation  Academic Article
• Laboratory measurement of the direct oral anticoagulants  Academic Article
• Letter to the Editor  Academic Article
• Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran  Academic Article
• Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation  Academic Article
• Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation  Academic Article
• Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin  Academic Article
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Academic Article
• Management of Anticoagulation Around Pacemaker and Defibrillator Surgery  Academic Article
• Management of bleeding complications in patients with cancer on DOACs  Academic Article
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting  Academic Article
• Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report  Academic Article
• Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done?  Academic Article
• Monitoring and reversal of direct oral anticoagulants  Academic Article
• Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial  Academic Article
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Academic Article
• Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™  Academic Article
• New Anticoagulants for Atrial Fibrillation  Academic Article
• New Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• New Anticoagulants for the Prevention of Thromboembolism  Academic Article
• New anticoagulants  Conference Paper
• New anticoagulants in atrial fibrillation management  Conference Paper
• New aspects on treatment modalities for thromboembolic episodes  Academic Article
• New oral anticoagulant agents – general features and outcomes in subsets of patients  Academic Article
• New oral anticoagulants and oculoplastic surgery  Academic Article
• New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions  Academic Article
• New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty  Academic Article
• New oral anticoagulants in elderly patients  Academic Article
• New oral anticoagulants: not quite there yet  Academic Article
• New oral anticoagulants: which one should my patient use?  Academic Article
• Newly Identified Events in the RE-LY Trial  Academic Article
• News at XI: moving beyond factor Xa inhibitors  Academic Article
• Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study  Academic Article
• Novel Oral Anticoagulants: A Focused Review for Stroke Physicians  Academic Article
• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism  Academic Article
• Novel oral anticoagulants in gastroenterology practice  Academic Article
• Novel oral anticoagulants in secondary prevention of stroke  Academic Article
• Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits  Academic Article
• Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants  Academic Article
• Oral Anticoagulant Therapy  Academic Article
• Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease  Academic Article
• Overview of the New Oral Anticoagulants  Academic Article
• Patient outcomes using the European label for dabigatran  Academic Article
• Perioperative Management of Dabigatran  Academic Article
• Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure  Academic Article
• Perioperative management of patients who are receiving a novel oral anticoagulant  Academic Article
• Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin  Academic Article
• Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran  Academic Article
• Periprocedural Management of Oral Anticoagulation  Academic Article
• Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy  Academic Article
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Academic Article
• Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation  Academic Article
• Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran  Academic Article
• Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management  Academic Article
• Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial  Academic Article
• Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients  Academic Article
• Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation  Academic Article
• Potential of new anticoagulants in patients with cancer  Academic Article
• Practical aspects of new oral anticoagulant use in atrial fibrillation  Academic Article
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban  Academic Article
• Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation  Academic Article
• Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment  Academic Article
• Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study  Academic Article
• Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure  Academic Article
• Preventing Alzheimer’s Disease  Academic Article
• Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran  Academic Article
• Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate  Academic Article
• RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate  Academic Article
• Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran  Academic Article
• Real-world variability in dabigatran levels in patients with atrial fibrillation: reply  Academic Article
• Real‐world variability in dabigatran levels in patients with atrial fibrillation  Academic Article
• Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial  Academic Article
• Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding  Academic Article
• Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation  Academic Article
• Reversal agents for current and forthcoming direct oral anticoagulants  Academic Article
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions  Academic Article
• Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study  Academic Article
• Reversal of direct oral anticoagulants: a practical approach  Academic Article
• Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)  Academic Article
• Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation  Academic Article
• Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants  Academic Article
• Risk of intracranial hemorrhage between different direct oral anticoagulants in older patients seen in the emergency department with a head injury: A population-based cohort study  Academic Article
• Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial  Academic Article
• Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation  Academic Article
• Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography  Academic Article
• Rivaroxaban for the prevention and treatment of venous thromboembolism  Academic Article
• Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis  Academic Article
• Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment  Academic Article
• Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial  Academic Article
• Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update  Academic Article
• Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial  Academic Article
• Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease  Academic Article
• Stroke prevention in atrial fibrillation: Closing the gap  Academic Article
• Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation  Academic Article
• The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2  Academic Article
• The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery  Academic Article
• The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients  Academic Article
• The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?  Academic Article
• The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study  Academic Article
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations  Academic Article
• The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses  Academic Article
• The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale  Academic Article
• The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect  Academic Article
• The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants  Academic Article
• The top 4 advances in antithrombotic care in the last year  Academic Article
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Academic Article
• Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis  Academic Article
• Treatment of acute pulmonary embolism with dabigatran versus warfarin  Academic Article
• Treatment of venous thromboembolism with dabigatran  Academic Article
• Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer  Academic Article
• Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014  Academic Article
• Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review  Academic Article
• Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial  Academic Article
• Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.  Academic Article
• Venous thromboembolism management: where do novel anticoagulants fit?  Academic Article
• What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review  Academic Article
• γT‐S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo  Academic Article
• ‘Real world’ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry  Academic Article